

Contract Number	Amount Obligated	Total Estimated Contract Value	Center	Awardee Name	Awardee Address	BAA WP Number	Description
75F40122C00146	\$2,014,369.00	\$2,014,369.00	CTP	Georgia Tech Research Corp	926 Dalney Street NW, Atlanta, GA 30332	TOXWP 118	In Vitro Assessment of Chemical Mixture-induced Airway Inflammation in Healthy and Diseased Lungs.
75F40122C00128	\$353,326.00	\$353,326.00	CDER	University of Wisconsin	21 N Park Street, Suite 6301, Madison, WI 53715	PMWP 186	Development of Modernized Susceptibility Guidance for Oral Cephalosporin Antimicrobial Agents Using Pharmacometric Approaches
75F40122C00147	\$400,000.00	\$400,000.00	CDER	The Regents of the University of Michigan	3003 S. State Street, Ann Arbor, MI 48109	PMWP 190	Advancing Methods to Optimize Antimicrobial Dosing in Patients with Obesity
75F40122c00180	\$291,618.00	\$291,618.00	CDER	Institute for Clinical Pharmacodynamics	242 Broadway STE 101, Schenectady, NY 12305	PMWP 191	Combatting Antibiotic Resistant Bacteria (CARB) Program
75F40122C00184	\$1,550,000.00	\$2,942,329.00	OC	Alliance NCTN Foundation	125 S Wacker Drive, STE 1600, Chicago, IL 60606	PMWP 194	Real World Collection of Radiographic Images and Treatment Emergent Adverse Event Data Next Phase Development of ICAREdata Research Institute
75F40122C00174	\$291,142.00	\$291,142.00	CDER	Institute for Clinical Pharmacodynamics	242 Broadway STE 101, Schenectady, NY 12305	PMWP 195	A study in the "Development Of Modernized Susceptibility Guidance for Oral Sulfamethoxazole-Trimethoprim Using Pharmacometrics Approaches

75F40122C00138	\$246,617.00	\$246,617.00	CDER	University of Southern California	3720 S Flower Street, FL 3, Los Angeles, CA 90007	PMWP 198	A study into modified susceptibility testing protocol for predicting polymyxin in vivo efficacy
75F40122C00187	\$100,000.00	\$100,000.00	OC	University of Oklahoma	PO BOX 26901 URP865, Suite 490, Oklahoma City, OK 73126	PMWP 213	Analyzing clinical outcomes and genomic data of American Indian patient population treated with immune checkpoint inhibitors for various cancers
75F40122C00112	\$1,783,975.93	\$3,177,482.71	CDRH	Synensys, LLC	145 Governors Square, Suite D, Peachtree City, GA 30269	PMWP 214	Improving the Reliability, Interoperability, Agility, and Quality of Laboratory Data Exchanges using System Safety Engineering and High Reliability Organization Methods
75F40122C00179	\$1,000,000.00	\$3,470,544.66	CDRH	College of American Pathologists	325 Waukegan Road, Northfield, IL 60093	PMWP 216	In Vitro Diagnostic (IVD) Encoded Test Result Data Validation and Quality Improvement
75F40122C00143	\$9,999,920.00	\$9,999,920.00	CDRH	Deloitte Consulting L.L. P	1919 N. Lynn Street, Arlington, VA 22209	PMWP 217	Optimizing Knowledge Management Processes that Enable a Highly Reliable Laboratory Data Life Cycle
75F40122C00130	\$407,720.00	\$407,720.00	CDER	Hartford Hospital	80 Seymour Street, Hartford, CT 06102	PMWP 218	Ex Vivo Modeling, Simulation, and In Vivo Pharmacokinetic Validation to Guide Antimicrobial Dosing Recommendations for Patients on Continuous Renal Replacement Therapy
75F40122C00134	\$399,991.00	\$399,991.00	CDER	Midwestern University	555 31 st Street, Downers	PMWP 219	Development and Validation of CRRT-specific

					Grove, IL 60515		Beta-Lactam Population Pharmacokinetic Models to Guide Treatment for Patients with Hospital-Acquired Pneumonia
75F40122C00161	\$3,795,000.00	\$3,795,000.00	CDRH	Safe Health Systems INC.	1475 N Scottsdale Road, STE 200, Scottsdale, AZ 85257	PMWP 229	Stimulate Innovation in Clinical Evaluations and Personalized Medicine to Improve Product Development and Patient Outcome
75F40122C00139	\$265,368.00	\$527,318.00	CDER	Uppsala Universitet	Dag Hammarskjolds Vag 7, 752 37, Uppsala, Sweden	PMQWP 299	Model-integrated strategies for bioequivalence evaluation of drugs with high variability and/or long half-life
75F40122C00163	\$709,554.00	\$709,554.00	CDER	DigiM Solution	2 Chestnut Street, Winchester, MA 01890	PMQWP 303	Correlative 3D Imaging and AI Analysis to Establish Critical Performance Attributes of Polymeric Microsphere Products in Support of Performance Evaluation
75F40122C00019	\$447,513.00	\$997,996.00	CDER	University of Texas	110 Inner Campus Drive, Austin, TX 78712	PMQWP 307	Correlation Between Material properties, Manufacturing process, Structural properties, and Quality Attributes of Long-acting, Biodurable Implants
75F40122C00123	\$300,255.00	\$300,255.00	CVM	Texas A&M University System	8441 Riverside Parkway, BLDG 1, STE 3, Bryan, TX 77807	PMQWP 334	In-Vitro Quality Metrics Approach for Bioequivalence Demonstration Between Intramammary Infusion Products of Animals

75F40122C00197	\$408,329.00	\$408,329.00	CDER	Inhalation Sciences	Halsovagen 7, Huddinge SE 141 57	PMQWP 343	A study in "DissolvIt an in vitro test model built to resemble relevant lung physiology for evaluating the dissolution- and absorption of drugs administered via the inhalation route
75F40122C00202	\$764,285.00	\$764,285.00	CDER	University of Sydney	The University of Sydney NSW 2006	PMQWP 345	Identification of Drug Distribution in Aerosols: A Nanospectroscopy and NanoThermal Analysis
75F40122C00121	\$160,376.00	\$494,060.00	CDER	Drexel University	3141 Chestnut Street, Philadelphia, PA 19104	PMQWP 353	Machine-Learning based Heterogeneous Treatment Effect Models for Prioritizing Product-Specific Guidance Development
75F40122C00192	\$3,000,000.00	\$3,000,000.00	CDER	National Institute for Pharmaceutical Technology and Education	717 Delaware Street SE, STE 482, Minneapolis, MN 55414	PMQWP 356	Continuous drug substance manufacturing from biomass-derived building blocks
75F40122C00182	\$1,844,289.00	\$1,844,289.00	CDER	University of Florida	1523 Union Road, Rm 207	PMQWP 359	Advancing In Vitro and (patho)Physiology-Based Pharmacokinetics Models to Understand and Predict Pulmonary Absorption and Tissue Retention of Inhaled Drugs
75F40122C00200	\$82,182,000.00	\$82,182,000.00	CBER	Massachusetts Institute of Technology	77 Massachusetts Ave, Cambridge, MA 02139	PMQWP 364	To Development of an Integrated Continue cGMP Facility for mRNA Manufacturing
75F40122C00186	\$2,692,771.30	\$2,692,771.30	CBER	Trustees of Princeton University	1 Nassau Hall, Princeton, NJ 08544	PMQWP 376	An Integrated Platform for Continuous RNA Nanoparticle Formulation and Drying

75F40122C00122	\$2,701,518.97	\$4,999,953.00	CDER	National Institute for Pharmaceutical Technology and Education	717 Delaware Street SE, STE 482, Minneapolis, MN 55414	PMQWP 387	A Model-Based Systems Engineering Approach to End-to-End Pharmaceutical Manufacturing of Liquid
75F40122C00155	\$224,632.00	\$393,716.00	CDRH	American Academy of Ophthalmology	655 Beach Street, Floor 3, San Francisco, CA 94109	EETWP 59	A study in Leveraging the real-world data from the American Academy of Ophthalmology's IRIS Registry to evaluate the use and impact of approved medical devices and software algorithms
75F40122C00183	\$943,192.00	\$943,192.00	CDRH	University of Missouri	5100 Rockhill Road, Kansas City, MO 64110	EETWP 60	KCCQ Validation in Tricuspid Valve
75F40122C00196	\$937,737.91	\$3,694,735.47	CDER	Critical Path Institute	1730 E River Road, STE 200, Tucson, AZ 85718	EETWP 63	A standardized framework to support FDA qualification of complex in vitro models for use in regulatory submissions
75F40122C00116	\$753,973.00	\$3,518,377.00	CDER	The Regents of the University of California	1855 Folsom Street, STE 425, San Francisco, CA 94103	EETWP 65	Community Uses of Psychedelics and Safety Study (CUPS)
75F40122C00203	\$6,523,977.04	\$47,223,589.66	CDRH	Nanobiosym INC.	245 First Street, STE 18, Cambridge, MA 02142	EETWP 66	Gene-RADAR Mobile Device & Nanobiosym Digital Dx Platform for Precision Mobile Diagnosis
75F40122C00154	\$2,032,775.00	\$2,032,775.00	CDER	Brigham and Women's Hospital INC.	75 Francis Street, Boston, MA 02115	HDDISWP 156	Real-world evidence to support labeling expansions for effectiveness claims using a two-stage trial emulation process

75F40122C00181	\$2,708,850.00	\$2,708,850.00	OC	Brigham and Women's Hospital INC.	75 Francis Street, Boston, MA 02115	HDDISWP 160	Calibrating RWE Studies in Oncology Against Randomized Trials
75F40122C00193	\$2,044,056.00	\$3,077,090.00	CDER	University of North Carolina	104 Airport Drive, CB# 1350, Chapel Hill, NC 27599	HDDISWP 167	Opioid Data Lab: Understanding Overdose Through Scientific Innovation
75F40122C00165	\$1,353,024.00	\$1,353,024.00	CDER	Denver Health and Hospital Authority	777 Bannock Street, Denver, CO 80204	HDDISWP 170	General Online Longitudinal Drug Survey: A novel approach to combining surveillance and longitudinal designs for investigating drug use trajectories
75F40122C00185	\$119,160.00	\$549,175.31	CDER	American College of Emergency Physician's	4950 W Royal Lane, Irving, TX 75063	HDDISWP 171	Analysis of Naloxone Usage, Safety, and Efficacy in the Emergency Department and Prehospital Environment During the COVID-19 Pandemic
75F40122C00168	\$400,756.00	\$400,756.00	CFSAN	Texas Tech University	2500 Broadway, Lubbock, TX 79409	FSSWP 19	Improving detection of plant contaminants in mixed samples with targeted sequencing of 353 nuclear protein coding genes
75F40122C00051	\$559,428.00	\$2,275,305.00	OC	The Children's Hospital of Los Angeles	4650 Sunset Blvd, Lost Angeles, CA 90027	MCMWP 103	Development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID19
75F40122C00169	\$623,991.00	\$623,991.00	NCTR	The University of Tennessee	62 S Dunlap Street, Memphis, TN 38163	MCMWP 126	Longitudinal Quantitative Evaluation of Clinical, Immunological, and Virological Characteristics of COVID-19 in Mucosal, Blood, and Fecal Specimens

							from Adults, Children, and Exposed Household Members
75F40122C00023	\$317,349.00	\$607,510.00	CDER	University of North Carolina	104 Airport Drive, STE 2200, Chapel Hill, NC 27599	SSBSWP 185	Reducing Preventable Medication Errors through Minimizing Work Distractions: Evaluating Data from Smart Pump Usage in Health Systems across the Midwest
75F40122C00137	\$855,584.00	\$855,584.00	OC	Americans for Indian Opportunity	1001 Marquette Ave NW, Albuquerque, NM 87102	SSBSWP 194	Increasing Participation in Clinical Trials and Research in Tribal and Urban Indigenous Communities
75F40122C00111	\$230,000.00	\$230,000.00	OC	National Minority Quality Forum, INC.	1201 15 th Street NW, STE 340, Washington, DC 20005	SSBSWP 198	Strengthening FDA's Ability to Communicate Health and Safety Information to Minority Populations About Pediatric COVID-19 Vaccines and Vaccine Boosters Utilizing Social Media Platforms
75F40122C00145	\$575,451.00	\$575,451.00	CDER	Anticoagulation Forum, INC.	17 Lincoln Street, Floor 2, Newton, MA 02461	SSBSWP 199	Oral Anticoagulation Surveillance and Improvement through Stewardship (OASIS)
75F40122C00148	\$1,997,031.00	\$1,997,031.00	CBER	New York Medical College	40 Sunshine Cottage Road, Valhalla, NY 10595	SSBSWP 201	Long-term Outcomes of COVID-19 Vaccine-associated Myocarditis
75F40122C00191	\$1,184,520.00	\$2,656,207.00	CDER	Northwestern University	750 N. Lake Shore Drive, Rubloff 7 th Floor, Chicago, IL 60611	SSBSWP 205	Assessing the Effectiveness of Text Enhancements to Prevent Drug Name Confusion Errors
Totals	\$141,557,687.24	\$202,527,229.11					

